BLTE News and Press, Belite Bio Inc From 11/25/23

2023-11-25 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will...

2023-11-14 23:30:05 ET Belite Bio, Inc. (BLTE) Q3 2023 Earnings Conference Call November 14, 2023, 04:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer ...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Belite Bio Inc (BLTE) is expected to report $-0.31 for Q3 2023

2023-11-14 03:36:49 ET More on Belite Bio Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead? Seeking Alpha’s Quant Rating on Belite Bio Historical earnings data for Belite Bio Financial information for Belite Bio For...

Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11 countries worldwide First subject dosed with Tinlarebant in pivotal global Phase 3 “PHOENIX” trial ...

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 8 th and 9 th are...

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will ...

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite Bio&...